You are visiting us from Virginia. You are located in HHS Region 3. Your Center is Central East ATTC.

Products and Resources Catalog

Center
Product Type
Target Audience
Language
Keywords
Date Range
Curriculum Package
Opioid abuse and addiction (e.g., heroin, OxyContin) remains a critical national public health concern. In 2002, tablet formulations of the medication Buprenorphine were approved by the Food and Drug Administration for the treatment of opioid addiction. In order to prepare the field to effectively integrated this new treatment, the Buprenorphine Treatment Blending Team developed an awareness training to disseminate information and enhance awareness among multidisciplinary (non-physician) addiction professionals about Buprenorphine treatment. This training is designed to provide a broad overview of the medication, its effects, and the role of non-physician practitioners in providing and supporting the treatment of individuals receiving this medication.      
Published: January 1, 2003
1 2 3

The ATTC Network understands that words have power. A few ATTC products developed prior to 2017 may contain language that does not reflect the ATTCs’ current commitment to using affirming, person-first language. We appreciate your patience as we work to gradually update older materials. For more information about the importance of non-stigmatizing language, see “Destroying Addiction Stigma Once and For All: It’s Time” from the ATTC Network and “Changing Language to Change Care: Stigma and Substance Use Disorders” from the Providers Clinical Support System (PCSS).

map-markermagnifiercrossmenuchevron-down